 |
인쇄하기
취소
|
Samil, Boehringer Ingelheim sign exclusive distribution agreement over Mobic cap.
Samil Pharm has signed an exclusive distribution agreement with Boeringer Ingelheim Korea to supply Mobic (meloxicma) in the domestic market.
“We are excited to enter into this collaboration with Boehringer Ingelheim, a research-driven pharmaceutical company,” a Samil official said.
“We believe that this partnership will promote both companies’ win-win strategy.”
Meloxicam is a nonster...
“We are excited to enter into this collaboration with Boehringer Ingelheim, a research-driven pharmaceutical company,” a Samil official said.
“We believe that this partnership will promote both companies’ win-win strategy.”
Meloxicam is a nonster...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.